Department of Urology, Cleveland Clinic, Glickman Urological and Kidney Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Hematol Oncol Clin North Am. 2011 Aug;25(4):717-36. doi: 10.1016/j.hoc.2011.04.007.
The majority of kidney cancer tumors are small renal masses (SRMs). Partial nephrectomy is now established as the preferred treatment modality. In some patients the potential morbidity may outweigh the oncologic risk. Based on active surveillance studies, restriction of radical therapy to patients with aggressive tumors has been proposed. This has spurred renewed interest in development of radiologic and biopsy-based diagnostic techniques that can identify high-risk disease. This article discusses the natural history and pathologic features of SRMs, the evolving role of biopsy, and provides an overview of outcomes of various treatment approaches and current recommendations for management.
大多数肾癌肿瘤为小肾肿块 (SRMs)。 部分肾切除术现在已成为首选的治疗方式。 在某些患者中，潜在的发病率可能超过肿瘤风险。 基于主动监测研究，建议将根治性治疗限制在侵袭性肿瘤患者中。 这激发了人们对开发可以识别高危疾病的放射学和基于活检的诊断技术的新兴趣。 本文讨论了 SRMs 的自然史和病理特征、活检的作用变化，并概述了各种治疗方法的结果以及目前的管理建议。
